Shares of Alexion Pharmaceuticals Inc. /zigman2/quotes/206262068/composite ALXN +0.03% were up 0.1% in trading on Thursday after the Securities and Exchange Commission said the drugmaker would pay more than $21 million to resolve charges that it paid officials in Russian and Turkey to promise its immunosuppressive drug Soliris. The company allegedly paid government officials between 2010 and 2015 to encourage prescriptions of Soliris and secure "favorable regulatory treatment" for the drug. There are also allegations that subsidiaries in Brazil and Colombia failed to main accurate records. Alexion did not admit fault or deny the SEC's findings. Soliris is Alexion's top-selling drug, bringing in about $3.9 billion in sales in 2019. Alexion's stock has gained 3.9% year-to-date, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -0.72% is down 3.5%.